Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 17/20 | 0.56 |
| ▸ | AR | P10275 | 4/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5502831 | 0.85 | ALDH1A1 (0.38) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL5506294 | 0.84 | PGR (0.65) | PGRARNR3C1NR3C2 | |
| SCHEMBL5503876 | 0.83 | PGR (0.39) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL5506240 | 0.81 | PGR (0.39) | PGRARNR3C1NR3C2 | |
| SCHEMBL5506748 | 0.80 | PGR (0.39) | PGRARNR3C1NR3C2 | |
| SCHEMBL5502297 | 0.80 | PGR (0.56) | PGRARNR3C1NR3C2ALDH1A1 | |
| SCHEMBL27685680 | 0.79 | BRD4 (0.39) | PGRNR3C1CREBBP | |
| SCHEMBL5498807 | 0.77 | PGR (0.37) | PGRARNR3C1NR3C2MAPT | |
| SCHEMBL5500041 | 0.77 | PGR (0.37) | PGRARNR3C1NR3C2KDM4E | |
| SCHEMBL5503833 | 0.77 | FABP4 (0.37) | PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | claimed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | claimed |
| EP-1778233-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006019716-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INC. | 2007-11-01 | — | — | US | disclosed |
| CN-101018552-A | Intracellular receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254917-A1 | INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS | CASR, GRK2, RYR2 | PGR 953/4885AR 486/4885NR3C1 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.